These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 20027118)

  • 1. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
    Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
    Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
    Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
    Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
    Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis.
    Yan F; Xu X; Chen Y; Deng Z; Liu H; Xu J; Zhou J; Tan G; Wu J; Zheng H
    Ultrasound Med Biol; 2015 Oct; 41(10):2765-73. PubMed ID: 26166460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent.
    Frinking PJ; Tardy I; Théraulaz M; Arditi M; Powers J; Pochon S; Tranquart F
    Ultrasound Med Biol; 2012 Aug; 38(8):1460-9. PubMed ID: 22579540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
    Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
    Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
    Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
    Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
    Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
    J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
    Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
    Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
    Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
    Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
    Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
    Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
    Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
    Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
    Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
    Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
    Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55.
    Hackl C; Schacherer D; Anders M; Wiedemann LM; Mohr A; Schlitt HJ; Stroszczynski C; Tranquart F; Jung EM
    Ultraschall Med; 2016 Jun; 37(3):290-6. PubMed ID: 27112624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
    Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
    Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGFR2-targeted molecular imaging in the mouse embryo: an alternative to the tumor model.
    Denbeigh JM; Nixon BA; Hudson JM; Puri MC; Foster FS
    Ultrasound Med Biol; 2014 Feb; 40(2):389-99. PubMed ID: 24342913
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.